v3.26.1
Revenue Recognition
 3 Months Ended
Mar. 31, 2026
Revenue Recognition [Abstract]  
REVENUE RECOGNITION

NOTE 3 – REVENUE RECOGNITION

 

The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or as services are performed. Revenue is measured based on the consideration the Company receives in exchange for those products

 

The following table presents the Company’s revenue by product category for the three months ended March 31, 2026, and 2025:

 

   For the Three Months Ended
March 31,		 
   2026   2025 
Training  $772,005   $144,920 
Product supplies   1,267,076    626,656 
Equipment   
-
    
-
 
Patient procedures   600,273    592,765 
Total revenue  $2,639,353   $1,364,341 

 

Listed below are the revenue, cost of revenue, gross profit, assets and net profit (loss) by Company and its subsidiary, Global Stem Cells Group, for the three months ended March 31, 2026:

 

   For the Three Months Ended 
   March 31, 2026 
   Global Stem Cells Group   Regenerative Medical Technology Group   Total 
             
Revenue  $2,639,353   $
-
   $2,639,353 
Cost of revenue   872,862    
-
    872,862 
Gross profit  $1,766,491   $
-
   $1,766,491 
Gross Profit %   66.93%   0.00%   66.93%
                
Assets  $3,261,189   $1,748,393   $5,009,582 
Net profit (loss)  $171,896   $(1,048,170)  $(876,274)